A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

This study compared efficacy and safety of TA4415V, a trastuzumab biosimilar, with reference trastuzumab in patients with human epidermal growth factor receptor 2 –positive (HER2-positive) early-stage breast cance...

Source: BMC Clinical Pharmacology - July 28, 2022 Category: Drugs & Pharmacology Authors: Reza Safaei Nodehi, Behjat Kalantari, Jahangir Raafat, Nafiseh Ansarinejad, Vahid Moazed, Seyed Mohammad Reza Mortazavizadeh, Mehran Hosseinzadeh, Bayazid Ghaderi, Arash Jenabian, Mojtaba Qadyani, Shirin Haghighat, Abolghasem Allahyari, Mehrzad Mirzania, Tags: Research Source Type: research